B cell activation
US6093693A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Nov 18, 1996 |
| Grant date | Jul 25, 2000 |
| Priority date | — |
| Expiry date | Nov 18, 2016 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S426/801
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A novel protein purified from bovine colostral whey and isolated nucleotide sequences encoding the protein. The isolated bovine protein has homology with human CD14 and murine CD14 and so is referred to as bovine CD14. A method of activating B cells, and particularly of activating B cells in a mammal, such as a human, in need of such activation by administering CD14 is described. CD14 can be incorporated into infant formula. CD14 can be administered to an infant, as by feeding to the infant such formula. CD14 can be incorporated as part of a vaccination. CD14 can be administered to a patient having a T cell immune deficiency, for example, a particular T cell dysfunction in which gp39 is under expressed on or totally absent from the cell surface of patient T cells. Preparation of medicaments including CD14 for activating B cells in a mammal in need of such activation is described. Natural or recombinant CD14 can be used.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.